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Summary
Ninety patients with tuberous-sclerosis complex (TSC)
were tested for subtle mutations in the TSC2 gene, by
means of single-strand conformational analysis (SSCA)
of genomic DNA. Patients included 56 sporadic cases
and 34 familial probands. For all patients, SSCA was
performed for each of the 41 exons of the TSC2 gene.
We identified 32 SSCA changes, 22 disease-causing mu-
tations, and 10 polymorphic variants. Interestingly, we
detected mutations at a much higher frequency in the
sporadic cases (32%) than in the multiplex families
(9%). Among the eight families for which linkage to the
TSC2 region had been determined, only one mutation
was found. Mutations were distributed equally across
the gene; they included 5 deletions, 3 insertions, 10 mis-
sense mutations, 2 nonsense mutations, and 2 tandem
duplications. We did not detect an increase in mutations
either in the GTPase-activating protein (GAP)–related
domains of TSC2 or in the activating domains that have
been identified in rat tuberin. We did not detect any
mutations in the exons (25 and 31) that are spliced out
in the isoforms. There was no evidence for correspon-
dence between variability of phenotype and type of mu-
tation (missense versus early termination). Diagnostic
testing will be difficult because of the genetic hetero-
geneity of TSC (which has at least two causative genes:
TSC1 and TSC2), the large size of the TSC2 gene, and
the variety of mutations. More than half of the muta-
tions that we identified (missense, small in-frame dele-
tion, and tandem duplication) are not amenable to the
mutation-detection methods, such as protein-truncation
testing, that are commonly employed for genes that en-
code proteins with tumor-suppressor function.
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Introduction
Tuberous-sclerosis complex (TSC) is an autosomal dom-
inantly inherited disease characterized by hamartomas;
the population frequency is 1/10,000–1/6,000 (Wied-
erholt et al. 1985; Osborne et al. 1991). A hamartoma
is defined as “a benign tumor-like nodule composed of
an overgrowth of mature cells and tissues that normally
occur in the affected part, but with disorganization and
often with one element predominating” (Dorland’s Il-
lustrated Medical Dictionary 1994). In individuals af-
fected with TSC, nearly every organ system has been
reported to have hamartomas. These growths rarely pro-
gress to malignancy, but they may cause morbidity and
mortality because of their size and location (Shepherd
et al. 1991). Common clinical findings include hypopig-
mented macules (HM), facial angiofibromas (FA), renal
angiomyolipomas (RA), cardiac rhabdomyomas, and
cortical tubers and subependymal glial nodules in the
brain (Roach and Delgado 1995). The greatest source
of morbidity is the brain tumors, which cause seizures
(in 80%–90% of affected individuals), mental retarda-
tion (in x50%–60% of affected individuals), and be-
havioral abnormalities (most prominently, autism; in
X50% of affected individuals) (Curatolo et al. 1991;
Gomez 1988; Hunt and Dennis 1987, respectively). Ap-
proximately two thirds of cases are sporadic and are
assumed to result from new mutations (Sampson et al.
1989).
Genetic heterogeneity is characteristic of TSC (Samp-
son et al. 1989; Janssen et al. 1990; Haines et al. 1991;
Northrup et al. 1992). Two loci on different chromo-
somes have been implicated as causes of the disease. One
locus (TSC1) maps to chromosome 9q34.3, and the
other (TSC2) maps to chromosome 16p13.3 (Fryer et
al. 1987; Kandt et al. 1992). Each locus accounts for
∼50% of familial cases (Kwiatkowski et al. 1993). Clon-
ing of the TSC1 gene has recently been reported (van
Slegtenhorst et al. 1997). The TSC2 gene, identified in
1993, is encoded by 41 exons, spanning ∼50 kb of ge-
nomic DNA (European Chromosome 16 TS Consortium
1993). Interestingly, the gene is adjacent, in a tail-to-tail
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fashion, to the PKD1 gene, which is the major gene
involved in autosomal dominant polycystic kidney dis-
ease (European Polycystic Kidney Disease Consortium
1994). The two genes (TSC2 and PKD1) are separated
by ∼800 bp of intervening sequence (Hughes et al.
1995). The protein encoded by TSC2, tuberin, is hy-
pothesized to function as a tumor-suppressor gene
(Green et al. 1994; Wienecke et al. 1995; Henske et al.
1996; Jin et al. 1996). Multiple isotypes of TSC2, iden-
tified on the basis of alternative splicing at two different
exons, have been reported (Xu et al. 1995). These iso-
types of TSC2 are thought to have different develop-
mental and tissue-specific expression patterns.
Mutations in the TSC2 gene have been reported in
familial and sporadic cases. Studies suggest that 2%–3%
of TSC2 mutations are large DNA deletions, some of
which encompass the entire TSC2 gene (European Chro-
mosome 16 Consortium 1993; Brook-Carter et al. 1994;
Au et al. 1997). More-subtle mutations are known to
cause disease; the literature includes multiple single-mu-
tation reports (Kumar et al. 1995a, 1995b; Vrtel et al.
1996), as well as a report in which 173 patients were
tested for mutations only in exons 34–38 (Maheshwar
et al. 1997). There are two reports in which the entire
TSC2 gene was surveyed for mutations: Wilson et al.
(1996), using an RT-PCR–based system, tested 30 pa-
tients, and van Bakel et al. (1997), using the protein-
truncation test, tested 18 patients. Using single-strand
conformational analysis (SSCA) of genomic DNA, we
tested 90 affected individuals (56 sporadic cases and 34
familial probands) for TSC2 mutations. SSCA has the
advantage that it screens for mutations at the genomic
level; this circumvents potential failure to detect muta-
tions that do not survive either the transcriptional or the
translational process. The goals of our study were two-
fold: first, to determine the type, number, and distri-
bution of mutations in the TSC2 gene, in an unselected
group of tuberous-sclerosis patients, and, second, to as-




Ninety patients (56 sporadic cases and 34 familial
probands from multiplex TSC families) were tested for
variation in the TSC2 gene. TSC diagnoses were reached
in accordance with standard diagnostic criteria (Gomez
1991; Roach et al. 1992). Parents of all sporadic patients
were examined carefully, and no findings consistent with
TSC were detected. Some parents underwent additional
clinical testing, including retinal examination, renal ul-
trasound, and/or computed tomography (CT) or mag-
netic resonance imaging (MRI) scan of the brain. If pos-
sible, blood samples for DNA extraction were obtained
from parents of sporadic patients (from both parents, in
38 cases; from the mother only, in 10 cases; from the
father only, in 2 cases; or from neither parent, in 6 cases).
In multigenerational families, as many family members
as possible were enrolled in the study (266 individuals
from 34 families). Among the 34 families, 8 showed
evidence for linkage to TSC2, and 4 showed evidence
for linkage to TSC1. In the remaining 22 families, link-
age could not be determined. Linkage in a family was
established on the basis of both a posterior probability
of 190% for linkage, as calculated by means of
HOMOG, to markers in either the TSC1 (markers
D9S114, D9S66, DBH, and D9S149) or the TSC2
(markers D16S291, KG8, TSC2 exon 40 EcoRV poly-
morphism, and D16S525) region and exclusion by
markers from the other region (Ott 1991). Four of the
families included two affected children, but, despite care-
ful examination and internal imaging studies, the parents
did not show any findings that were consistent with the
diagnosis of TSC. Informed consent was obtained from
all individuals enrolled in the study. Patients included
62 (69%) Caucasians, 13 (14%) African Americans, 12
(13%) Hispanics, 2 (2%) Caucasian Hispanics, and 1
(1%) Japanese. The study was approved by the insti-
tutional review boards at the University of Texas Med-
ical School, in Houston, and at the University of Texas
Southwestern Medical School and the Scottish Rite Hos-
pital, both in Dallas.
SSCA
For all amplifications, primer pairs were designed to
flank each exon and to include consensus splice junc-
tions. Primers, therefore, extended ∼30–50 bp before
and after each exon. Two overlapping sets of primers
were designed for exon 33 because of its large size (571
bp). Sufficient sequence information was available from
GenBank for all exons except exons 21, 25, and 36.
Sequences of the introns that precede and of those that
follow exons 21, 25, and 36 were obtained by sequenc-
ing PCR fragments amplified from primers that were
derived from the exons that flank introns 20, 21, 24,
25, 35, and 36. For all of the exons except 8, 12, 13,
19, 20, and 22, amplification by PCR was accomplished
with the initial set of primers. For these remaining six
exons, a second set of primers was designed. We were
able to obtain a good result by using either the second
primer set or a combination of primers from the first
and second sets. Information on the sequences of primer
pairs, the sizes of PCR products, and the PCR conditions
have been submitted to the Genome Data Base (GDB).
The 42 GDB accession numbers are the even numbers
6053944–6054026.
PCR reactions were performed in 20-ml reaction
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mixtures that contained 40 ng genomic DNA, 1–2 mM
primer pairs, 1 mCi [32P]-dCTP, 200 mM dNTPs, and 1
U Taq DNA polymerase (Boehringer Mannheim), in
standard PCR buffer. Two microliters of the PCR prod-
ucts were denatured at 100C for 10 min, chilled in ice
bath, and loaded into wells of a 6% native Tris-borate
EDTA PAGE gel (19 acrylamide:1 bisacrylamide). The
samples were electrophoresed, with constant power set
at 2 W, at 4C for 16–22 h, depending on the size of
the PCR product. After electrophoresis, the gel was vac-
uum dried and subjected to autoradiography. When var-
iants were detected by SSCA, we tested either the par-
ents, in the case of sporadic patients, or other family
members, in the case of multigenerational families.
Changes that were verified either as unique, in sporadic
patients, or as segregating with the disease, in the mul-
tigenerational families, were tested further.
Direct Sequencing
SSCA variants that were unique to the sporadic and
the familial patients were followed up by direct sequenc-
ing of the variant bands, reamplified in a subsequent
PCR, with the excised variant PAGE-gel band as tem-
plate (Calvert et al. 1995). The center section of the
variant band was excised and transferred into a 0.5-ml
Eppendorf tube that contained 20 ml 1 # PCR buffer.
The gel was rehydrated in the 1 # buffer at 65C for
10 min, and reamplification PCR was performed in a
final volume of 50 ml, under the same conditions. The
PCR products were then fractionated on a 3% Nusieve
or Metaphor agarose gel to remove excess primers and
products of spurious amplifications. Bands near the ex-
pected size range were excised and processed in accor-
dance with the b-agarose (New England Biolabs) treat-
ment protocol. Supernatant was sequenced by the
Molecular Genetics Core Facility, Department of Mi-
crobiology and Molecular Genetics, University of Texas
Medical School, Houston. This strategy was successful
∼80% of the time. In the remaining cases, it was not
possible to excise the pure variant bands. For these var-
iants, the PCR products were subcloned into pGEM-T
vector for further analyses.
Additional verification of mutations was accom-
plished in one of two ways: If a change resulted in cre-
ation or loss of a restriction-enzyme site, we tested the
affected individual, the individual’s parents, and a panel
of control individuals, to confirm that the change was
present only in the TSC patient. In sporadic cases with
a change that did not involve a restriction-enzyme site,
we sequenced the same exons from both parents and a
control. In all cases except exon 16, the changes deter-
mined to be disease-causing mutations were unique
among the 90 affected individuals.
Results
Mutations and Polymorphisms
A total of 32 variants were detected by SSCA. Of
these, 22 variants, found in 21 patients, were unique
changes that appear to be disease related (table 1).
Changes comprised 5 deletions, 3 insertions, 10 missense
mutations, 2 nonsense mutations, and 2 tandem dupli-
cations. All the missense mutations involved changes of
amino acids that are conserved between the mouse, rat,
and human sequence of TSC2. Mutations were relatively
evenly distributed over the exons of the gene (fig. 1).
Mutations were found in 18 (32%) of the 56 sporadic
patients, compared with only 3 (9%) of the 34 multi-
generational families. Thirteen of the 21 mutations were
detected in 62 Caucasian patients, 6 in 13 African Amer-
ican patients, and 2 in 12 Hispanic patients. The finding
of a greater percentage of mutations among the African
American patients was not statistically significant (P 
)..057
For several exons (9, 14, 16, and 23), we identified a
mutation in two different individuals. One patient was
found to have a five-amino-acid tandem duplication, in
exon 9, and a missense mutation, Leu1750Phe, in exon
40; neither of these mutations was observed in any of
the other 89 patients tested. The mother of the patient
did not have either of the changes, and the father was
unavailable. The other mutation identified in exon 9 was
a missense mutation, Leu292Pro. We identified two mu-
tations in exon 14: a 4-bp deletion (526SerFSr533X)
and a nonsense mutation (Arg505X). The nonsense mu-
tation has been reported elsewhere (Wilson et al. 1996).
In exon 16, we found the same missense mutation,
Arg611Gln, in two unrelated sporadic cases. Wilson et
al. (1996) reported a missense mutation, Arg611Trp, in
the same codon of exon 16. In exon 23, we identified
two mutations—a nonsense mutation (Cys877X) and a
missense mutation (Arg905Trp)—in African American
sporadic cases. In both cases, the mother and father were
tested, and the change was found to arise de novo. Of
the three mutations that we identified in multigenera-
tional families, one was a missense mutation in exon 29,
Arg1200Trp, which we found in a large African Amer-
ican family. Wilson et al. (1996) reported the same mu-
tation in a Caucasian family. There was no clustering of
mutations in the exons that comprise the putative GAP-
related domain (exons 34–38) in our population. We
found four mutations in the region, in exons 34–37. We
did not identify any mutations in either exon 25 or exon
31, which are the spliced exons in the different isoforms
of TSC2. Figure 2 provides both representative examples
of the SSCA changes and follow-up sequencing that
identifies the respective mutations.
Ten of the changes represent polymorphic variation.
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Table 1
TSC2 Mutations in Sporadic and Familial Patients
Patient Exon DNA Sequence Changea Codon Change Consequence
TS94-35 5 del2bp (T487–T488) 163PheFSr187X Frameshift (early termination)
TS92-05 8 ins1bp (C831–C–C832) 277CysFSr337X Frameshift (early termination)
TS91-03 9 15-bp tandem dup (C900–C914) Amino acids 300–304 tandemly repeated (GMALW) 5-Amino-acid tandem duplication
TS94-02 9 875TrC Leu292Pro Missense
TS87-144 14 del4bp (G1577–CCT1580) 526Ser FSr533X Frameshift (early termination)
TS94-96 14 1513CrTb 505Argrstop Nonsense (early termination)
TS94-31 16 1832GrAc Arg611Gln Missense
TS93-29 16 1832GrAc Arg611Gln Missense
TS94-104 18 del1bp (C2070/2071) 690Phe FSr697X Frameshift (early termination)
TS94-82 21 ins2bp (C2490–AT–A2491) 830Leu FSr948X Frameshift (early termination)
TS94-86 23 2661TrA 887Cysrstop Nonsense (early termination)
TS95-12 23 2713CrT Arg905Trp Missense
HOU23 24 ins1bp (C2779–C2784) 928ProFSr939X Frameshift (early termination)
TS87-117 27 3252CrG Asp1084Glu Missense
HOU11 29 3598CrTb Arg1200Trp Missense
TS93-41 30 17-bp tandem dup
(G3611–G3627)
1209Leu FSr1215X Frameshift (early termination)
TS93-44 32 3887ArT Asp1295Val Missense
TS93-20 34 del4bp (A4475–A4478) 1492Ser FSr1574X Frameshift (early termination)
TS92-08 35 4577ArG Tyr1526Cys Missense
TS93-14 36 del (4770–4772) dl Ile 1591 In-frame deletion
TS94-53 37 4859ArT Asn1620Ile Missense
TS91-03 40 5179CrT Leu1727Phe Missense (see exon 9)
a Nucleotide numbering is based on the published sequence X75621 (GenBank); nucleotide A of the initiation codon ATG is the reference
nucleotide number 1.
b An identical change was reported by Wilson et al. (1996).
c A change in the same codon was reported by Wilson et al. (1996).
Two of the polymorphic variants caused loss or gain of
a restriction-enzyme site (Au et al. 1997).
Clinical Findings
Clinical data for each of the patients in whom a mu-
tation was identified are displayed in table 2. Every pa-
tient in whom a mutation was identified has HM and
positive brain-imaging (CT or MRI) findings. Other clin-
ical findings varied between patients.
Discussion
In an unselected TSC population, our rate of identi-
fication of mutations by means of a combination of
Southern blotting, for large intragenic deletions, and
SSCA of genomic DNA, for more subtle changes, is
25%. Our first phase of testing by Southern blotting
detected two mutations in 92 individuals; one individual
was the proband in a multiplex family, and the other
was a sporadic case (Au et al. 1997). These two indi-
viduals were eliminated from our second phase of test-
ing. Disease-causing mutations were identified in 21 of
the remaining 90 affecteds. Using estimates derived from
family studies, we would predict that 45 patients in our
sample have mutations in the TSC2 gene (Kwiatkowski
et al. 1993). Therefore, our overall rate of mutation
detection by SSCA is 47%. In general, the SSCA method
is predicted to detect 76% and 63% of mutations in
DNA fragments of sizes 212 bp and 250 bp, respectively
(Sheffield et al. 1993). In our population, which included
34 families with more than one affected, we identified
mutations in only 3 families, whereas we found muta-
tions in 18 of the 56 sporadic cases. If the denominators
are decreased to account for the TSC1 mutations present
in half of the individuals, our detection rates are 18%
(3/17) for familial cases and 64% (18/28) for sporadic
cases. The detection rate for sporadic cases is approxi-
mately the same as the rate expected for the SSCA
method; the remaining 36% of cases required other de-
tection methods (i.e., heteroduplexes, dideoxy-finger-
printing, or CFLP cleavase) (Keen et al. 1991; Liu and
Sommer 1994; Brow and Fors [in press]). It is important
to determine which mutation-screening method is best,
for the sake of future diagnostic testing. Our strategy
(SSCA of genomic DNA) detected more mutations
among sporadic cases (32%) than did the reverse tran-
scriptase–PCR strategy of Wilson et al. (1996) (19%).
The majority of TSC cases, approximately two thirds,
are sporadic in nature. Our method of mutation screen-
ing excluded attempts at detection of mutations in the
regulatory elements at the 5′ and 3′ UTRs. It is difficult
to prove that variants in the regulatory elements are
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Figure 1 Schematic illustration of the distribution of TSC2 mutations detected in 21 TSC patients. The sizes of exons and introns are
not drawn to scale. The locations of the putative transmembrane domains (TM1, TM2, TM3, and TM4) were predicted from the primary
amino acid sequence encoded by GenBank sequence X75621, and they reside in exons 5, 13, 15, and 21, respectively. Other functional domains
defined experimentally include transcriptional activation domains AD1 and AD2, found in rat tuberin, and GAP-like domains, specific to Rapla
(RaplGAP) and to Rab5 (RAB5GAP). The numbers 1, 5, 10, 20, 25, 30, 35, and 40 appear above the corresponding exons, for clarification.
Exons denoted by blackened boxes are found in all isoforms of tuberin, and exons denoted by shaded boxes are spliced in some isoforms. Each
vertical solid line below an exon represents a single frameshift or nonsense mutation predicted to cause premature termination of tuberin. Each
vertical dotted line below an exon represents a single missense mutation predicted to change a single amino acid in that exon. Exons 9, 14,
16, and 23 each harbored two mutations, and the two missense mutations found in exon 16 were identical (Arg611Gln) but occurred in two
unrelated patients.
disease-causing mutations; they cannot be distinguished
easily from rare polymorphic variants, which are not
uncommon in the TSC2 gene (Au et al. 1997; authors’
unpublished observation).
There are several possible explanations for our ina-
bility to find mutations in the multigenerational families.
By chance, our sample may include more families that
harbor a mutation in the TSC1 gene. We have no reason
to assume that this is the case; in fact, among the families
in our sample, only four show definite evidence of link-
age to TSC1, whereas eight show evidence of linkage to
TSC2. We did not selectively include or eliminate any
of our patients, except the two excluded patients in
whom we had previously detected large intragenic mu-
tations of TSC2. Another possible explanation is that
familial mutations are more difficult to detect by means
of the methods that we employed. We did find two
unique intronic variants within 40 bp of the splice sites;
both variants are in familial cases and have not yet been
categorized as mutations or polymorphisms. We are test-
ing whether these intronic mutations would cause in-
correct splicing and would thereby lead to production
of abnormal or decreased amounts of tuberin. If these
changes prove to be mutations, our rate of detection in
multiplex families increases to 15% (5/34), which is still
less than the predicted rate.
Of the mutations identified, 10 were missense muta-
tions, 2 were in-frame tandem duplications or deletions,
and the other 10 were predicted to result in premature
termination of the protein. Therefore, 150% of the mu-
tations that we detected would be missed by strategies
that rely on production of a smaller protein product.
The majority (6/9) of mutations detected by Wilson et
al. (1996) were of the former type (missense, in frame,
etc.), which led them to conclude that, in terms of mu-
tations, the behavior of the TSC2 gene is similar to the
behavior of the p53 gene (Baker et al. 1990; Chiba et
al. 1990; Toguchida et al. 1992). If we combine all of
the mutations reported by others, the total in each cat-
egory (14 missense/in-frame duplications or deletions vs.
17 truncating mutations) is similar to the distribution
that we observed (12 missense/in-frame duplications or
deletions vs. 10 truncating mutations), with a slight bias
toward truncating mutations. This is not surprising,
since one group (van Bakel et al. 1997) tested only for
truncating mutations (Kumar et al. 1995a, 1995b; Vrtel
et al. 1996; Maheshwar et al. 1997; van Bakel et al.
1997). We predict that, as the database of TSC2 mu-
tations grows, TSC2 will continue to exhibit the trend
observed in other phakomatoses—that is, more frame-
shifts and nonsense mutations than missense mutations
(Latif et al. 1993; Legius et al. 1993; Trofatter et al.
1993).
Our findings and those of other investigators indicate
a total of 46 mutations, identified in 52 independent
patients (Kumar et al. 1995a, 1995b; Vrtel et al. 1996;
Wilson et al. 1996; Maheshwar et al. 1997; van Bakel
et al. 1997). Only four mutations (Arg505X,
Arg611Gln, Arg1200Trp, and Pro1675Leu) were de-
tected in more than a single individual, and a small num-
ber of exons (14, 16, 29, and 38) were more likely to
harbor mutations. Of these four exons, only exon 38 is
known to be in a functional domain of tuberin, whereas
the other three have not yet been identified as having
specific functions in the protein. We are targeting these
exons in our current functional studies of tuberin. We
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Figure 2 Typical SSCA gel variants and characterization of each mutation by sequencing. A, Six typical SSCA variants (arrowheads),
found in six sporadic TSC probands (TS91-03, TS94-02, TS94-104, TS94-82, TS94-86, and TS93-20 codes above corresponding lanes), in
exons 9, 18, 2l, 23, and 34 of the respective patients’ TSC genes. These SSCA variants are unique among 90 TSC probands and their parents.
The SSCA-variant bands were excised and reamplified for sequencing; results are shown in B. The location of each mutation is indicated by
an arrow above each variant. Sequences for exons are presented for review of the forward sense-strand sequences, except for exon 21, for
which the reverse-complemented sequence is shown. The 15-bp duplication found on exon 9 of patient TS91-03 is bracketed. Both patient
TS94-02 and patient TS94-86 have substitution mutations; the sequence of normal TSC2 is shown, with an arrow, above the mutation. Two
deletion mutations in patients TS94-104 and TS93-20 are shown; deleted sequences (boxes) appear above the deletion sites. In patient TS94-
82, the mutation contains a 2-bp (AT) insertion, indicated by an arrowhead.
identified five transition mutations that represent
changes in the CpG dinucleotides of the Arg-specific co-
don, as observed in the NF2 gene (Rouleau et al. 1993);
this finding is similar to findings reported by Wilson et
al. (1996).
We found two tandem duplications. This type of mu-
tation has been reported in only two other human dis-
ease genes: the NF1 gene and the CO12A1 gene (Tiller
et al. 1990; Tassebehji et al. 1993). Wilson et al. (1996)
also reported a tandem-duplication mutation in the
TSC2 gene. The mutation detected in individual TS91-
03 (15-bp tandem duplication) supports the theory that
this type of mutation occurs as a result of intrastrand
slipped mispairing during meiosis, because it is flanked
by two short direct repeats (TGGG) (Roth et al. 1985).
No repeat sequences flanking the tandem duplication
were observed, either in individual TS93-41 or in the
29-bp duplication reported by Wilson et al. (1996). In-
terestingly, both duplications in exons 30 and 35 oc-
curred at the 5′ end of the exon; this suggests a separate
but perhaps similar mechanism.
Although we did observe mutations in the Rap1GAP-
related domain (exons 35–39), the Rab5GAP-related do-
main (exons 38–40), and the transcriptional activating
domains (exons 29, 30, 40, and 41 ) identified in the
rat tuberin, we did not observe a higher number of mu-
tations in these regions than in the rest of the gene (Wie-
necke et al. 1995; Maheshwar et al. 1997; Tsuchiya et
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HEARTHM FA UF SP CT MRI Tumors Cysts
TS94-35 (18 years)            
TS92-05 (1 year)             
TS91-03 (9 years)           
TS94-02 (12 years)             
TS87-144 (20 years)          
TS94-96 (19 years)           
TS94-3l (10 years)             
TS93-29 (30 mo)           
TS94-104 (19 years)          b
TS94-82 (16 mo)            
TS94-86 (12 years)             
TS95-12 (42 mo)           
HOU23-01 (32 years)           
TS87-117 (3 mo)          
HOU11-58 (11 years)          
TS93-41 (22 years)           
TS93-44 (7 years)        
TS93-20 (5 years)             
TS92-08 (22 years)             
TS93-14 (5 years)            
TS94-53 (5 years)           b 
NOTE.—MR/DD  mental retardation or developmental delay; BA/LD  behavioral abnormalities or learning disabilities, a plus sign ()
denotes presence; and a minus sign () denotes absence.
a All patients with positive CT or MRI findings had subependymal nodules and one or more cortical tubers.
b See Discussion.
al. 1996; Xiao et al. 1997). Patients who had mutations
in these particular exons did not have a more severe
phenotype compared with patients who had mutations
in other regions of the gene. We did not identify any
mutations in the exons (25 and 31) known to be spliced
out in different isoforms (Xu et al. 1995).
Although the significance of frameshift mutations is
obvious (production of prematurely terminated tuberin),
determination of the significance of missense mutations
is more difficult. All the missense mutations that we ob-
served changed amino acids that are conserved among
mouse, rat, and human tuberin. Eight of the 10 missense
mutations were observed in sporadic cases; 5 of these
(Arg611Gln, Arg905Trp, Asp1295Val, Tyr1526Cys,
and Asn1635Ile) were verified as de novo, since both
parents were available for testing, and neither parent
had the change. One of the missense mutations
(Arg1200Trp) detected in a family had been observed
elsewhere, and the mutation could be traced back to the
starting point, for verification (Wilson et al. 1996).
Clinical findings for each patient are summarized in
table 2. The mutations can be divided into two groups:
those predicted to lead to premature termination of tub-
erin (frameshifting insertions/deletions and nonsense
mutations) and those that do not lead to premature ter-
mination of tuberin (missense mutations and in-frame
deletions). The 10 patients with truncating mutations
have more skin findings (FA, found in 9 patients; ungual
fibromas [UF], in 7 patients; and shagreen patch [SP],
in 8 patients) compared with the 11 patients in the mis-
sense and in-frame–deletion group (FA, found in 5 pa-
tients; UF, in 0 patients; and SP, in 3 patients). Similarly,
six of eight patients in the premature-termination group
have RA, compared with only three of eight in the other
group. However, others have noted that skin conditions
associated with TSC increase as an affected individual
ages (Webb et al. 1996). Examination of the clinical
findings as they correspond to age, in our sample of
patients with identifiable mutations, reinforces this ob-
servation. Our 9 “older” patients (x12 years of age)
had a greater number of skin findings (8, 6, and 7 pa-
tients had FA, UF, and SP, respectively) and RA (in 7
patients) than did our 12 “younger” patients (!12 years
of age), among whom 6, 1, 4, and 2 patients had FA,
UF, SP, and RA, respectively. The majority (7/10) of the
patients with truncating mutations are in the older
group; only 2 of the 11 patients in the missense and in-
frame–deletion group fall into the older age bracket. We
conclude on the basis of these data that type of germ–line
mutation does not influence clinical phenotype.
Of 21 patients in whom a mutation was detected, 16
were evaluated for renal cysts. A definite diagnosis of
renal cysts was reached in one case (HOU23-01). Two
of our patients (TS94-104 and TS94-53) had MRI scans
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of the abdomen, to evaluate the kidneys. In both cases,
multiple focal areas of abnormal signal intensity were
observed throughout the kidney; these were interpreted
as compatible with renal cysts. We have tested these
individuals for involvement of the PKD1 gene, by means
of loss-of-heterozygosity (LOH) studies of flanking
markers (KG8, which is at the 3′ end of PKD1, and
D16S665, at the 5′ end of PKD1), and we find no LOH.
Our studies do not indicate involvement of PKD1 in
these patients. Brook-Carter et al. (1994) described a
contiguous-gene syndrome, associated with a severe cys-
tic renal phenotype, that includes both the TSC2 and
PKD1 genes. They point out that renal cysts have been
observed in chromosome 9–linked TSC patients, and
that the number of patients observed with the TSC2-
PKD1 contiguous-gene syndrome is small and does not
account for the majority of TSC patients reported to
have renal cysts. We agree with Brook-Carter et al.
(1994) that cysts can be seen as part of the TSC phe-
notype, on the basis of TSC2 mutations alone.
In summary, diagnostic testing for TSC will be difficult
because of the genetic heterogeneity of TSC (which has
at least two causative genes: TSC1 and TSC2), the large
size of the TSC2 gene, and the variety of mutations.
More than half of the mutations that we identified (mis-
sense, small in-frame duplication, and tandem duplica-
tion) are not amenable to the mutation-detection meth-
ods, such as the protein-truncation test, that are
commonly employed for genes that encode proteins with
tumor-suppressor function. Identification of mutations
in the TSC2 gene supplies additional clues toward iden-
tification of functionally important regions of the gene.
There appears to be no correlation between the type of
mutation and the clinical findings. Renal cysts can be
seen in TSC patients who have TSC2 mutations, without
involvement of the PKD1 gene.
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